Tudor Investment Corporation is a Connecticut-based hedge fund founded by billionaire Paul Tudor Jones II in 1980. Mr. Jones, a graduate of the University of Virginia, is famous for his macro trading and bets on swings in interest rates and currencies. Mr. Tudor stands at 308th position on the Forbes list of the richest people in the world, with a total worth of $4.7 billion. As per its latest 13F filing, Tudor Investment manages a portfolio worth $4.71 billion.
While Tudor Investment has a long history of successful investing, it is currently in the midst of tough times. Tudor’s macro money strategy is failing to perform amid changing dynamics in the global economy. Last week, Bloomberg reported that Tudor laid off 15% of its workforce amid losses and investor withdrawals. In a statement, Tudor Investment said that as a result of the changing operating environment, the fund had made some “strategic adjustments” to its staffing, without specifying the number of jobs cut. Amid the dry spell and investor exodus, Paul Tudor Jones, in his fund’s latest letter to investors, pledged to manage a big chunk of their money himself. Having that in mind, let’s see some of the biggest moves by Tudor Investment Corporation during the second quarter, as revealed in its latest 13F filing.
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).
Hologic, Inc. (NASDAQ:HOLX)
– Shares Owned by Tudor Investment Corporation (as of June 30): 1.31 million
– Value of Tudor Investment Corporation’s Holding (as of June 30): $45.35 million
Tudor Investment acquired over 1.26 million shares of Massachusetts-based women’s health products company Hologic, Inc. (NASDAQ:HOLX) during the second quarter, ending the period with a stake worth around $45.35 million. Hologic has recently been awarded $4.1 million by the US Department of Health and Human Service for the development of a blood-screening test to detect the Zika virus. The company reported third quarter of fiscal year 2016 EPS of $0.51 on $717 million in revenue, above the estimates of $0.48 in EPS and $704.27 million in revenue. The stock is down by 0.90% year-to-date. Arthur B Cohen and Joseph Healey’s Healthcor Management LP owns 4.00 million shares of Hologic, Inc. (NASDAQ:HOLX) as of the end of the second quarter.
Express Scripts Holding Company (NASDAQ:ESRX)
– Shares Owned by Tudor Investment Corporation (as of June 30): 526,800
– Value of Tudor Investment Corporation’s Holding (as of June 30): $39.93 million
Tudor Investment increased its holding in Express Scripts Holding Company (NASDAQ:ESRX) by a lofty 822% during the second quarter, adding 469,664 shares of the company to its equity portfolio. Earlier this month, Express Scripts released a list of drugs that it will no longer cover in 2017, including Bristol-Myers Squibb Co (NYSE:BMY)’s arthritis medication Orencia, Eli Lilly and Co (NYSE:LLY)’s new psoriasis medication, and Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s Zyclara cream. Jefferies Group cut its price target on Express Scripts to $88 from $98 last month after the company released its second quarter earnings, though it maintained its ‘Buy’ rating on the stock, which has lost over 12% in 2016. At the end of the second quarter, Andy Brown’s Cedar Rock Capital owned around 4.92 million shares of Scripts Holding Company (NASDAQ:ESRX).
On the next page, we’ll discuss three more big purchases made by Tudor Investment in the second quarter.